These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37355792)

  • 1. Study of Efficacy of Injection Remdesivir in Patients of COVID-19.
    Chaudhary BR; Dudhrejia PJ; Gambhir RM; Rathod MM
    J Assoc Physicians India; 2023 Apr; 71(4):11-12. PubMed ID: 37355792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.
    Mozaffari E; Chandak A; Zhang Z; Liang S; Thrun M; Gottlieb RL; Kuritzkes DR; Sax PE; Wohl DA; Casciano R; Hodgkins P; Haubrich R
    Clin Infect Dis; 2022 Aug; 75(1):e450-e458. PubMed ID: 34596223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir.
    Santos Bravo M; Alonso R; Soria D; Sánchez Palomino S; Sanzo Machuca Á; Rodríguez C; Alcamí J; Díez-Fuertes F; Simarro Redon À; Hurtado JC; Fernández Avilés F; Bodro M; Rubio E; Villanueva JL; Vergara A; Castro P; Tuset M; Cuesta G; Puerta P; García C; Mosquera Gutiérrez MDM; Martínez MJ; Vila J; Soriano A; Marcos MÁ
    Microbiol Spectr; 2022 Dec; 10(6):e0244822. PubMed ID: 36354320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Remdesivir in children with COVID-19: report of an Italian multicenter study.
    Romani L; Roversi M; Bernardi S; Venturini E; Garazzino S; Donà D; Krzysztofiak A; Montagnani C; Funiciello E; Calò Carducci FI; Marabotto C; Castagnola E; Salvini F; Lancella L; Lo Vecchio A; Galli L; Castelli Gattinara G;
    Ital J Pediatr; 2024 Feb; 50(1):32. PubMed ID: 38413992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients.
    Coelho L; Falcão F; Póvoa P; Viegas E; Martins AP; Carmo E; Fonseca C; Campos L; Mansinho K; Carmo I; Soares J; Solano M; Mendes D; Miranda AC; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
    Sci Rep; 2023 Mar; 13(1):4482. PubMed ID: 36934143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment.
    Polivka L; Gajdacsi J; Fazekas L; Sebok S; Barczi E; Hidvegi E; Sutto Z; Dinya E; Maurovich-Horvat P; Szabo AJ; Merkely B; Müller V
    J Glob Health; 2022 Aug; 12():05031. PubMed ID: 36040909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.
    Filtz A; Carandina A; Fasiello A; Barbetta L; Lombardi R; Cinque F; Rizzi G; Ceriani E; Furlan L; Bellocchi C; Fracanzani AL; Hu C; Cogliati C; Canetta C; Peyvandi F; Montano N; Tobaldini E
    Intern Emerg Med; 2023 Mar; 18(2):359-366. PubMed ID: 36539604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effect of Remdesivir on some biomarkers in Iraqi patients with coronavirus 2019 (COVID-19): A cross-sectional study.
    Abdul Khaleq MA
    J Med Life; 2023 Aug; 16(8):1231-1234. PubMed ID: 38024833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.